Literature DB >> 21063684

Rs710521[A] on chromosome 3q28 close to TP63 is associated with increased urinary bladder cancer risk.

Marie-Louise Lehmann1, Silvia Selinski, Meinolf Blaszkewicz, Michael Orlich, Daniel Ovsiannikov, Oliver Moormann, Christoph Guballa, Alexander Kress, Michael C Truss, Holger Gerullis, Thomas Otto, Dimitri Barski, Günter Niegisch, Peter Albers, Sebastian Frees, Walburgis Brenner, Joachim W Thüroff, Miriam Angeli-Greaves, Thilo Seidel, Gerhard Roth, Holger Dietrich, Rainer Ebbinghaus, Hans M Prager, Hermann M Bolt, Michael Falkenstein, Anna Zimmermann, Torsten Klein, Thomas Reckwitz, Hermann C Roemer, Dietrich Löhlein, Wobbeke Weistenhöfer, Wolfgang Schöps, Anwer E Beg, Muhammad Aslam, Gergely Bánfi, Imre Romics, Katja Ickstadt, Holger Schwender, Andreas Winterpacht, Jan G Hengstler, Klaus Golka.   

Abstract

Single nucleotide polymorphism (SNP) rs710521[A], located near TP63 on chromosome 3q28, was identified to be significantly associated with increased bladder cancer risk. To investigate the association of rs710521[A] and bladder cancer by new data and by meta-analysis including all published data, rs710521 was studied in 1,425 bladder cancer cases and 1,740 controls that had not been included in previous studies. Blood samples were collected from 1995 to 2010 in Germany (n = 948/1,258), Hungary (n = 262/65), Venezuela (n = 112/190) and Pakistan (n = 103/227) supplemented by a meta-analysis of 5,695 cases and 40,187 controls. Detection of a A/G substitution (rs710521) on chromosome 3q28, position 191128627 was done via fast real-time polymerase chain reaction (rt-PCR). Rs710521[A] is associated with increased risk in the unadjusted analysis (OR = 1.21; 95% Cl = 1.04-1.40; P = 0.011) and in the recessive model adjusted for age, gender, smoking habits and ethnicity (OR = 1.23; 95% Cl = 1.05-1.44; P = 0.010). No difference between individuals occupationally exposed versus not occupationally exposed to urinary bladder carcinogens was observed concerning the relevance of rs710521[A]. Similarly, rs710521[A] did not confer different susceptibility in smokers and non-smokers. Performing a meta-analysis of 5,695 cases and 40,187 controls including all published studies on rs710521, a convincing association with bladder cancer risk was obtained (OR = 1.18; 95% Cl = 1.12-1.25; P < 0.0001). However, the odds ratio is relatively small.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21063684     DOI: 10.1007/s00204-010-0617-6

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  15 in total

1.  European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene.

Authors:  Thorunn Rafnar; Sita H Vermeulen; Patrick Sulem; Gudmar Thorleifsson; Katja K Aben; J Alfred Witjes; Anne J Grotenhuis; Gerald W Verhaegh; Christina A Hulsbergen-van de Kaa; Soren Besenbacher; Daniel Gudbjartsson; Simon N Stacey; Julius Gudmundsson; Hrefna Johannsdottir; Hjordis Bjarnason; Carlo Zanon; Hafdis Helgadottir; Jon Gunnlaugur Jonasson; Laufey Tryggvadottir; Eirikur Jonsson; Gudmundur Geirsson; Sigfus Nikulasson; Vigdis Petursdottir; D Timothy Bishop; Sei Chung-Sak; Ananya Choudhury; Faye Elliott; Jennifer H Barrett; Margaret A Knowles; Petra J de Verdier; Charlotta Ryk; Annika Lindblom; Peter Rudnai; Eugene Gurzau; Kvetoslava Koppova; Paolo Vineis; Silvia Polidoro; Simonetta Guarrera; Carlotta Sacerdote; Angeles Panadero; José I Sanz-Velez; Manuel Sanchez; Gabriel Valdivia; Maria D Garcia-Prats; Jan G Hengstler; Silvia Selinski; Holger Gerullis; Daniel Ovsiannikov; Abdolaziz Khezri; Alireza Aminsharifi; Mahyar Malekzadeh; Leonard H van den Berg; Roel A Ophoff; Jan H Veldink; Maurice P Zeegers; Eliane Kellen; Jacopo Fostinelli; Daniele Andreoli; Cecilia Arici; Stefano Porru; Frank Buntinx; Abbas Ghaderi; Klaus Golka; José I Mayordomo; Giuseppe Matullo; Rajiv Kumar; Gunnar Steineck; Anne E Kiltie; Augustine Kong; Unnur Thorsteinsdottir; Kari Stefansson; Lambertus A Kiemeney
Journal:  Hum Mol Genet       Date:  2011-07-12       Impact factor: 6.150

2.  Genetic susceptibility to bladder cancer risk and outcome.

Authors:  Jian Gu; Xifeng Wu
Journal:  Per Med       Date:  2011-05       Impact factor: 2.512

3.  Development of a custom next-generation sequencing panel for the determination of bladder cancer risk in a Tunisian cohort.

Authors:  Imen Hemissi; Sami Boussetta; Hamza Dallali; Faycel Hellal; Geoffroy Durand; Catherine Voegele; Haroun Ayed; Selim Zaghbib; Zeineb Naimi; Mouna Ayadi; Mohamed Chebil; James Mckay; Florence Le Calvez-Kelm; Slah Ouerhani
Journal:  Mol Biol Rep       Date:  2021-12-01       Impact factor: 2.316

4.  Genetic variants confer susceptibility to urinary bladder cancer: an updated list of confirmed polymorphisms.

Authors:  Silvia Selinski
Journal:  EXCLI J       Date:  2012-11-14       Impact factor: 4.068

5.  Current developments in toxicology.

Authors:  J D Stewart; R Marchan
Journal:  EXCLI J       Date:  2012-10-31       Impact factor: 4.068

6.  Bladder cancer epidemiology and genetic susceptibility.

Authors:  Haiyan Chu; Meilin Wang; Zhengdong Zhang
Journal:  J Biomed Res       Date:  2013-03-25

7.  Distinct SNP combinations confer susceptibility to urinary bladder cancer in smokers and non-smokers.

Authors:  Holger Schwender; Silvia Selinski; Meinolf Blaszkewicz; Rosemarie Marchan; Katja Ickstadt; Klaus Golka; Jan G Hengstler
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

8.  The post GWAS era: strategies to identify gene-gene and gene-environment interactions in urinary bladder cancer.

Authors:  Silvia Selinski
Journal:  EXCLI J       Date:  2014-11-03       Impact factor: 4.068

9.  Highlight report: Functional consequences of urinary bladder cancer risk variants.

Authors:  Silvia Selinski
Journal:  EXCLI J       Date:  2013-12-05       Impact factor: 4.068

10.  Improved genotyping of N-acetyltransferase 2: role of the ultra-slow acetylators.

Authors:  Meinolf Blaszkewicz
Journal:  EXCLI J       Date:  2013-12-05       Impact factor: 4.068

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.